Plain-English translation of NCT07167693 on ClinicalTrials.gov ↗ ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , an amino acid given intravenously, to see if it can help people with type 2 diabetes recover faster from diabetic ketoacidosis — a life-threatening condition where the body becomes too acidic and dangerously dehydrated. Researchers believe the medication may help restart your body's natural insulin production within minutes, which could speed up the clearing of harmful ketones from your blood. You would receive the treatment (or a placebo) as part of your emergency care, alongside all the standard treatments doctors normally use.
Some adults with type 2 diabetes can develop diabetic ketoacidosis, a serious emergency that can happen suddenly. Current treatments work, but they can take many hours. This medication may jumpstart your pancreas to make more insulin naturally, potentially shortening how long this dangerous condition lasts.
You likely qualify if…
You likely don't qualify if…
When you arrive at the emergency department with diabetic ketoacidosis, you would be screened and enrolled quickly. You would receive a 30-minute intravenous infusion of either the test medication or a placebo (salt water), given alongside all your standard emergency care for high blood sugar. The study team would draw blood samples at a few time points during and shortly after the infusion to measure your insulin levels and how quickly your ketones are clearing. Your participation focuses on this acute emergency visit — the main study measurements happen within the first 90 minutes.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States